Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.56 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in choroid plexus epithelial cells | 0.75 |
| chemistry Open Targets | compounds already reach it: zimeldine, trifluoperazine hydrochloride, sb-773812 +71 | 1.00 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 19 Parkinson's papers of 1,043 | 0.61 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11458
Earlier readings: 2026-10-26 0.49; 2026-10-25 0.49; 2026-10-24 0.49; 2026-10-23 0.49.
Sealed predictions
- HTR2A in dopamine neurons, braak+0.00 (p 1.000) → +0.42 (p 0.258)receipt 0578
- HTR2A in dopamine neurons, resilience+0.29 (p 0.223) → +0.09 (p 0.811)receipt 0114
- HTR2A in dopamine neurons, braak+0.10 (p 0.540) → +0.02 (p 0.908)receipt 0113
Swarm cases
receipt 0578: HTR2A in dopamine neurons, braak
- power
- full sample +0.10 (p 0.702, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.702, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.561, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.21, sign flips 2; without severely affected donors +0.10 (p 0.702, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HTR2A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0114: HTR2A in dopamine neurons, resilience
- power
- full sample +0.15 (p 0.449, n 55), 95% CI -0.12 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.20 (p 0.313, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: +0.21 (p 0.274, n 55). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.25, sign flips 0; without severely affected donors +0.16 (p 0.432, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for HTR2A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0113: HTR2A in dopamine neurons, braak
- power
- full sample +0.05 (p 0.680, n 84), 95% CI -0.17 to +0.26. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: +0.08 (p 0.475, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: -0.04 (p 0.721, n 84). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.08, sign flips 0; without severely affected donors +0.07 (p 0.544, n 75). fragile.
- cell type
- strongest in oligodendrocytes: +0.57 (p 2.1e-8, n 84) vs +0.05 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HTR2A in dopamine neurons.
follow-up confirmed in ventral tegmental area.
follow-up HTR2A · oligodendrocytes · braak: ventral tegmental area +0.34 p 0.0019 (needs p < 0.0028)
Receipts
loading the receipts